Clinical trials: Androgens
Prostatic Neoplasm
A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma
One current hypothesis as to what limits duration of initial hormone response is the rapid emergence of hormone resistant prostate carcinoma cells.
- Trial name
- NCT00001266
- Testing
- Suramin
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Adrenal Insufficiency, Excess Androgen
Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia
Background: Congenital adrenal hyperplasia (CAH) is a genetic disorder of the adrenal gland. The adrenal gland is located in the abdomen and produces small amounts of hormones such as cortisol, aldosterone, and androgen.
- Conditions
- Adrenal Insufficiency, Excess Androgen, Congenital Adrenal Hyperplasia (CAH)
- Trial name
- NCT01859312
- Testing
- Hydrocortisone (Solucortef), Insulin pump (Medtronic)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Metastatic Cancer, Prostate Cancer
Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases
RATIONALE: Paricalcitol may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. It may also stop the growth of tumor cells in bone.
- Trial name
- NCT00634582
- Testing
- paricalcitol, immunoenzyme technique, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
This study addresses the global topic of treatment optimization, i.e. achieving similar benefit while reducing the duration of treatment, hence hoping to decrease the burden of side-effects, improve quality-of life and reduce…
- Trial name
- NCT05974774
- Testing
- iMAB, cMAB
- Where
- 9 sites in Denmark, France and 1 more
- Volunteers
- 1,600 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
The Investigators Collected 534 PCOS Patients as the Case Group,and 580 Infertile Women With Normal Ovulatory Cycle of the Control Group;, At the Same Time, the Investigators Continuedly Collect Cases to October 2012, and Totally Collected 579 Patients With PCOS Altogether;
The Potential Biochemical Diagnosis Criteria and Therapeutic Effect Indexes: Sex Hormone Binding Globulin Levels and Free Androgen Index in Blood of Patients With Polycystic Ovary Syndrome
To explore whether Free androgen index（FAI）can be regarded as biochemically diagnostic indexes of high androgen hormone in blood of patients with Polycentric ovary syndrome（PCOS）.
- Conditions
- The Investigators Collected 534 PCOS Patients as the Case Group,and 580 Infertile Women With Normal Ovulatory Cycle of the Control Group;, At the Same Time, the Investigators Continuedly Collect Cases to October 2012, and Totally Collected 579 Patients With PCOS Altogether;, 534 Patients in the Cases Group and 580 Women in the Control Group Received no Measures, While 579 Patients Received Drugs;, The Investigators Monitored Basic Indexes in Blood of All the Subjects in This Suvey,and Also Monitored Indexes of 579 Patients After Treatment.
- Trial name
- NCT01784380
- Testing
- Diane-35;metformin;Clomiphene citrate; Human menopausal gonadotropin
- Where
- 2 sites in China
- Volunteers
- 1,159 people
- Sponsor
- Zhongshan Bo Ai Hospital
Androgenetic Alopecia
A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia
In this proof-of-concept study, the safety and efficacy of a solution formulation will be investigated in male subjects with androgenetic alopecia (AGA) after twice daily application for up to 26 weeks.
- Trial name
- NCT02279823
- Testing
- CB-03-01 solution, Minoxidil Solution 5%
- Where
- 3 sites in United States
- Volunteers
- 95 people
- Sponsor
- Intrepid Therapeutics, Inc.
Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma)
CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer
This is a prospective, randomized, open-label, phase II multicenter clinical trial evaluating the efficacy and safety of radical prostatectomy in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) who…
- Conditions
- Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Trial name
- CONVERT-HB1 (NCT07268794)
- Testing
- Androgen Deprivation Therapy (ADT), Docetaxel, PARP Inhibitors and Other Systemic Agents
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Fudan University
Cardiovascular Morbidity, Androgen Deficiency
Cross-sectional Study of 1200 Recreational Athletes With Former or Current Use of Androgenic Anabolic Steroids
Overarching aim of project Performance and image enhancing drugs (PIEDs) are pharmacological agents acquired illicitly to improve physical strength and endurance as well as to obtain a leaner and more muscular appearance.
- Conditions
- Cardiovascular Morbidity, Androgen Deficiency, Heart Failure
- Trial name
- FIDODK/BIC (NCT05178537)
- Testing
- AAS users
- Where
- Denmark
- Volunteers
- 1,200 people
- Sponsor
- Jan Frystyk
Stage IV Prostate Cancer, Bone Metastases
Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Ketoconazole may suppress the production of hormones and may interfere in the growth of prostate cancer cells. Alendronate sodium may be effective in preventing bone metastases and bone pain associated with prostate…
- Conditions
- Stage IV Prostate Cancer, Bone Metastases, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
- Trial name
- NCT00019695
- Testing
- alendronate sodium, ketoconazole
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Prostate CA, Androgen Deprivation Therapy
Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer
This study is for men with prostate cancer who are experiencing hot flashes due to treatments that lower testosterone. Hot flashes can affect your quality of life and make it harder for patients to continue their treatment, so…
- Trial name
- FLASH (NCT06972875)
- Testing
- Fezolinetant
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Vermont
Fertility Disorders
TRAP Study: Testosterone for Androgen Receptor Polymorphism
To determine whether pretreatment with transdermal testosterone increases the number of cumulus-oocyte complexes (COCs) obtained after ovarian stimulation by more than 1.5 in patients with low ovarian reserve and androgen…
- Trial name
- TRAP (NCT06195163)
- Testing
- Transdermal Gel in Sachet Dosage Form, No pretreatment
- Where
- Spain
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Instituto Bernabeu
Triple Negative Breast Cancer
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer
To facilitate the clinical testing of seviteronel and dexamethasone (SEVI-D) in combination with docetaxel in androgen receptor (AR) positive triple-negative breast cancer.
- Trial name
- 4CAST (NCT04947189)
- Testing
- Seviteronel-D (Seivteronel in combination with dexamethasone), Docetaxel
- Where
- Australia
- Volunteers
- 65 people
- Sponsor
- St Vincent's Hospital, Sydney
Prostate Cancer
Factors Affecting Androgen Deprivation Therapy Choice in Prostate Cancer Patients
The objective of this study is to investigate possible factors that will affect the choice of androgen deprivation therapy in prostate cancer patients.
- Trial name
- NCT05202340
- Testing
- No intervention
- Where
- Hong Kong
- Volunteers
- 100 people
- Sponsor
- Chinese University of Hong Kong
Recurrent Prostate Cancer
Bipolar Androgen-based Therapy for Prostate Cancer (BAT)
The purpose of this study is to determine the safety and clinical effects of alternating androgen deprivation therapy with testosterone therapy in men with recurrent prostate cancer as first line hormonal therapy, to assess the…
- Trial name
- BAT (NCT01750398)
- Testing
- Testosterone cypionate, Goserelin, Leuprolide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Prostate Cancer, Intermitent Anti-androgen Therapy
Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC
To evaluate the efficacy and safety of intermittent use of darolutamide compared to long-term use in combination with ADT and docetaxel in the treatment of mHSPC patients.
- Trial name
- NCT06177015
- Testing
- Darolutamide continuous, Darolutamide intermittent
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Prostate Cancer
Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as flutamide, bicalutamide, leuprolide, buserelin, and goserelin, may lessen the amount of androgens made by the body.
- Trial name
- DART (NCT00651326)
- Testing
- bicalutamide, buserelin, flutamide
- Where
- 13 sites in Canada
- Volunteers
- 48 people
- Sponsor
- NCIC Clinical Trials Group
Salivary Gland Cancer
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
Salivary Gland (SG) Cancers are a rare and heterogeneous group of tumors, usually approached by multidisciplinary teams in high specialized centers. Until today no standard of care exists to treat these cancers.
- Trial name
- NCT01969578
- Testing
- bicalutamide + triptorelin, Cisplatin + Doxorubicin, Carboplatin + Paclitaxel
- Where
- 26 sites in Austria, Belgium and 6 more
- Volunteers
- 149 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Castration Resistant Prostate Cancer
Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer
This is a single-institution, single-arm, open-label Phase 2 trial evaluating evofosfamide in subjects with M1 CRPC who fail first-line ARSIs.
- Trial name
- EVO (NCT06836726)
- Testing
- Evofosfamide
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- University Health Network, Toronto
Hyperandrogenemia, Obesity
Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction
This study will test whether longer-term suppression of adrenal function can ameliorate androgen (male hormone) overproduction in overweight early pubertal girls with androgen excess.
- Conditions
- Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
- Trial name
- NCT01422733
- Testing
- Hydrocortisone, dexamethasone, Cosyntropin
- Where
- United States
- Sponsor
- University of Virginia
Solid Tumours
Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer
This study aims to evaluate the combination of GSK525762 with other agents that have been shown to be effective in the treatment of CRPC or metastatic (m)CRPC.
- Trial name
- NCT03150056
- Testing
- GSK525762, Abiraterone, Enzalutamide
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 73 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.